)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
GRI Bio
GRI Bio (GRI) investor relations material
GRI Bio Corporate Connect Webinar Series summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Corporate Connect Webinar Series summary11 Feb, 2026
Key presentations and program updates
GRI Bio presented its pipeline of immune modulators targeting inflammatory, fibrotic, and autoimmune diseases, highlighting an oral RAR beta gamma agonist and NKT-cell modulators.
Lead program GRI-0621 showed positive phase 2A results in idiopathic pulmonary fibrosis (IPF), meeting safety and tolerability endpoints and demonstrating robust biomarker improvements.
Biomarker data indicated reduced fibrosis and signs of lung repair, with improved forced vital capacity (FVC) outcomes compared to standard of care.
GRI-0621 exhibited a favorable safety profile, with fewer gastrointestinal side effects and no exacerbation of common adverse events seen in current therapies.
GRI-0803, targeting regulatory T-cells, is advancing toward IND filing for systemic lupus erythematosus, with preclinical data showing reduced inflammation and improved kidney function.
Industry context and competitive differentiation
Current IPF treatments slow lung function decline but do not halt or reverse disease; GRI-0621 showed potential for disease modification and epithelial repair.
The safety and tolerability of GRI-0621 may enable combination therapies, aligning with industry trends toward multi-mechanism approaches.
Biomarker and gene expression data from GRI-0621 align with preclinical models, supporting its differentiated mechanism and potential for broader application.
The company is open to strategic partnerships for advancing to phase 2B and pivotal studies, seeking partners with complementary resources and expertise.
IPF remains a high unmet need, with current drugs generating over $4 billion annually despite limited efficacy and tolerability.
Forward-looking statements and milestones
Preparation for a phase 2B trial of GRI-0621 is underway, including drug manufacturing and feasibility work.
IND-enabling studies for GRI-0803 are expected to conclude this year, with an IND filing planned to initiate a phase 1 trial in systemic lupus erythematosus.
Early biomarker and clinical signals provide confidence for advancing to later-stage studies, with ongoing evaluation of combination strategies.
The company is actively engaging in discussions with potential partners to support next-stage clinical development.
Focus remains on addressing unmet needs in fibrotic and autoimmune diseases through innovative immune modulation.
GRI-0621's disease-modifying potential impact?
Ideal partner profile for GRI-0621 Phase 2B?
GRI-0803's market opportunity in SLE?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next GRI Bio earnings date
Q1 202615 May, 2026
GRI Bio
Next GRI Bio earnings date
Q1 202615 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
GRI Bio Inc. is a biotechnology company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases. The company specializes in modulating natural killer T (NKT) cells to target immune system dysregulation. Its research and development efforts aim to advance novel small-molecule drug candidates for conditions with high unmet medical needs. The company is headquartered in La Jolla, California, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage